Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase
Executive Summary
FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable
You may also be interested in...
Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use
FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting
Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use
FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market